On the other hand, the clinical trials on semaglutide (Wegovy) for weight loss have been clear: On average, people taking that medication lose 15% of their body weight over 68 weeks compared to 2.4% of body weight in those taking a placebo
161 Over a period of 24 weeks, all dosage groups of retatrutide showed significant improvements in reducing glycated hemoglobin (HbA1c) and body weight compared to the placebo group, especially in the higher dosage groups
If liver fat reduction is a key objective, retatrutide offers substantially greater hepatic fat clearance than tirzepatide, as discussed above
Note: whole-food supplements are not a substitute for a healthy dietthey are a supplement to an already good diet
Patients choosing between oral and injectable options deserve clear, honest information about what theyre selecting
Its not uncommon for new medications to cause some initial disruption as your body adjusts